COMMUNICATION

Artificial metalloenzymes for the diastereoselective reduction of NAD⁺ to NAD²H†

Tommaso Quinto, Daniel Häussinger, Valentin Köhler and Thomas R. Ward*

Stereoselectively labelled isotopomers of NAD(P)H are highly relevant for mechanistic studies of enzymes which utilize them as redox equivalents. Whereas several methods are firmly established for their generation in high diastereomeric purity by enzymatic methods, alternative methods have so far not been investigated. The article presents the stereoselective deuteration of NAD⁺ at the 4-position (90% de) of the pyridinium-ring by means of an artificial metalloenzyme. The artificial metalloenzyme consists of a biotinylated iridium cofactor embedded in streptavidin isoforms and the resulting constructs have been previously shown to be compatible with natural enzymes. Alternative methods for stereoselective NAD(P)⁺ reduction are expected to be of high interest for the mechanistic study of enzymes that accept NAD(P)H mimics and for the synthesis of structurally related fine chemicals.

Introduction

The coenzymes NAD(P)⁺ and NAD(P)H play a crucial role in the redox machinery of living systems. This relates to their ability to either accept a hydride at the C4-position of the pyridine ring in their oxidized form or to donate the respective hydride in the reverse-reaction (Scheme 1). When the hydride is replaced by a deuteride in the reduction step, two diastereo-isomers can be formed, due to the presence of the enantiopure adenine dinucleotide moiety. The diastereoisomers thus differ only in their configuration at C4. Stereoselective labelling of the coenzymes with deuterium or tritium yields precious mechanistic information for the corresponding enzymes. Methods for their preparation in high stereoisomeric purity are well established.[1–3]

Biocatalysis gains an ever increasing share in modern chemical manufacture, boosted by powerful protein engineer-

Department of Chemistry, University of Basel, Spitalstrasse 51, CH-4056 Basel, Switzerland. E-mail: thomas.ward@unibas.ch

†Electronic supplementary information (ESI) available: ¹H NMR spectra with water suppression and selective ¹H-TOCSY NMR spectra. See DOI: 10.1039/c4ob02071e

ing strategies.[4] NAD(P)H or NAD(P)⁺ mol equivalents are required in various biotransformations, including ketoreductases, alcohol dehydrogenases, Baeyer Villiger monooxygenases, imine reductases, and P450s.[5–8] These co-substrates are typically regenerated enzymatically in a catalytic concurrent fashion.[9] However, alternative approaches employing *e.g.* chemocatalysis or electrochemical reduction have received increasing attention since they offer additional flexibility in process conditions and are readily transferrable to NAD(P)-mimics, which are substantially cheaper than their natural analogues.[10]

One complex which has been frequently used in non-enzymatic regeneration systems for the transfer of reducing equivalents to NAD(P)⁺ is the achiral [RhCp*(bipy)(H₂O)]²⁺.[11] At least one report exists where an enantiopure complex was utilized.[12] However, no labelling studies were undertaken and accordingly, no diastereoselectivity for the reduction step studied. We recently reported on the application of an artificial transfer hydrogenase (ATHase) for the concurrent regeneration of NADH in a monooxygenase-coupled reaction.[13] To generate the artificial metalloenzyme, a biotinylated iridium pianostool complex was incorporated into streptavidin-mutant S112A (Fig. 1). The biotinylated ligand for the IrCp* moiety is achiral in the vicinity of the metal center and the respective complex has been shown to induce only negligible stereocontrol in the reduction of prochiral imine substrates in the absence of streptavidin (Sav). However, upon incorporation into Sav, substantial stereocontrol can be achieved.[14] Importantly, the concurrent process with the monooxygenase and other enzymes was only effective, when the complex was located inside Sav; otherwise dramatic deactivation of the monooxygenase and/or the artificial Ir-cofactor occurred.[13]

We have previously shown that substrate reduction with ATHases derived from streptavidin mutants S112A and S112K lead to *R*- and *S*-enantiomers for both ketones and imines, respectively.[14] The corresponding X-ray structures of [Cp*Ir(Biot-*p*-L)Cl] ⊂ S112A[14] and [Cp*Ir(Biot-*p*-L)Cl] ⊂ S112K[15] were recently reported and analysed: for S112A, the absolute configuration at [Cp*Ir(Biot-*p*-L)Cl] is (*S*) and for S112K, the

Scheme 1 Deuteration of NAD$^+$ at the C4 position yields diastereoisomers.

Fig. 1 NAD$^+$ reduction, (a) with a biotinylated Ir–complex and deuterated sodium formate in the absence of streptavidin mutants proceeds with low diastereoselectivity. (b) Upon incorporation into streptavidin mutants, the reduction proceeds with high diastereoselectivity. The star symbolizes a mutation in streptavidin.

absolute configuration is (R). Based on modeling studies, we hypothesise that the absolute configuration at Ir by-and-large determines the absolute configuration of the alcohol and amine products: we term this phenomenon "induced lock-and-key" whereby the protein determines the configuration of the metal which in turn dictates which prochiral face of the substrate is reduced.[15]

Here we report on the diastereoselectivity of NAD deuteration employing the Ir-cofactor by itself and upon incorporation into two Sav-mutants (Fig. 1).

Results and discussion

To determine the diastereomeric ratio after reduction with deuteride, ^{1}H-NMR-spectroscopy offers a convenient means.[16,17] This technique enables the direct determination of the diastereoselectivity in the reaction mixture without requiring isolation of the products. The only noteworthy differences

to potential preparative reactions lie in the presence of a small amount of deuterium oxide (5%), the dissolution of the biotinylated Ir-complex in DMF-d_7 instead of DMF and a short centrifugation step. Based on catalysis results obtained in asymmetric imine reduction[14] and NADH regeneration[13] with artificial metalloenzymes, the selectivity with two representative mutants was investigated. Mutant S112A, employed previously for concurrent NADH regeneration, leads to superior enantiomeric excess and high turnover numbers in the reduction of 1-methyl-6,7-dimethoxy-3,4-tetrahydroisoquinoline yielding (R)-configured salsolidine (up to 96% ee).[14] Reduction of the same substrate with the AME based on S112 K, in contrast, leads to a bias in favour of the (S)-enantiomer (up to 78% ee).[14]

For the stereoselective NAD$^+$ reduction experiments, deuterated sodium formate was used as a deuteride source in the presence of [Cp*Ir(biot-p-L)Cl]·S112A Sav and NAD$^+$. Following centrifugation, the crude reaction mixtures were analyzed by ^{1}H NMR spectroscopy. While background signals of the

protein and other components of the crude reaction mixture prevented unambiguous integration of 1D ^{1}H-NMR data, a selective one-dimensional TOCSY NMR experiment using irradiation on H6 (5.89 ppm) yielded clean spectra with sufficient signal to noise ratio to reliably integrate the two resonances attributed to both diastereomers (Fig. 1). As the TOCSY transfer occurs with slightly different efficiency for $(4R-^2H)$-NADH and $(4S-^2H)$-NADH, a calibration TOCSY experiment with commercial, non-deuterated NADH was performed (Fig. 2a) and the resulting integrals ($1.00 : 1.13$ for $H4_S : H4_R$) were used to normalize the integrals of the deuterated species (Fig. 2b–d). Due to the collapse of the $^2J_{HH}$ coupling constant of 18.1 Hz into a $^2J_{HD}$ of 2.8 Hz, both H4 resonances appear as broad singlets in the TOCSY spectrum and the fine structure is lost. The integration yielded a de of 87% for mutant S112A and a de of 90% for mutant S112K, while a de of 38% was obtained for the sample without Sav (all with an error margin of ±1%), after 16 hours reaction time (Fig. 2).

The modest, but significant diastereoselectivity observed in the absence of Sav, arises most likely from substrate control considering the formation of basically racemic product from achiral starting materials in related transformations.[13,14] Both

mutants led to a significant improvement in the diastereomeric excess compared to the result obtained in the absence of streptavidin (Fig. 2).

Interestingly, for the NAD$^+$ reduction, both S112A and S112K ATHases afford the same diastereomer preferentially. This observation stands in stark contrast with results previously reported for ketone and imine reduction whereby S112A and S112K afford (R)- and (S)-reduction products respectively. In a matched-mismatched spirit, we speculate that the inherent chirality of the sugar moiety of NAD$^+$ counterbalances the ATHase preference. This is supported by the inherent preference of the substrate in the absence of Sav. Alternatively, one NAD$^+$ substrate could bind in the biotin vestibule in S112A, thus modifying the environment of the metal complex. Similar results were computed for the imine reductase with S112A.[15] The preparation and screening of further mutants might provide guiding answers towards the design of ATHases with inverted selectivities for the reduction of NAD$^+$.

Conclusions

The high chiral induction observed is promising for further applications such as the investigation of specificity in enzymes utilizing NAD(P)-mimics and the resulting information would be of interest for future enzyme engineering tasks. Furthermore, related prochiral structures can be envisaged, namely 3,4 substituted pyridinium ions, which would provide valuable building blocks upon asymmetric conversion.[18]

Experimental part

Nicotinamide adenine dinucleotide hydrate (NAD$^+$, contains 10% H$_2$O) was purchased from Sigma. ^{2}HCOONa was purchased from ABCR. Streptavidin was prepared as previously reported.[13] [Cp*Ir(biot-p-L)Cl] was a kind gift from M. Dürrenberger and prepared as reported in ref. 19. NMR experiments were performed at 25 °C (MeOH calibration) on a Bruker Avance III NMR spectrometer operating at 600 MHz proton frequency, equipped with a direct detection dual channel, broadband probe-head with z-gradient. Chemical shifts were referenced against proton solvent peaks (4.773 ppm for H$_2$O). The selective TOCSY experiment[20,21] was performed using a MLEV17 spinlock sequence with a mixing time of 120 ms, trim pulses of 2.5 ms and a selective Gauss shaped refocusing pulse of 80 ms duration.

Stock solutions: buffer 1: sodium phosphate 50 mM, pH 7.5; buffer 2: ^{2}HCOONa 200 mM, sodium phosphate, pH 7.5 (^{2}HCOONa (138 mg) was dissolved in H$_2$O (5 ml), sodium phosphate buffer (0.5 ml, 1 M) was added and the pH adjusted to 7.5 by addition of aq. NaH$_2$PO$_4$. Water was added to a total volume of 10 ml); NAD$^+$ stock solution: 10 mM in buffer 1 (NAD$^+$ (29.9 mg, 405 μmol) was dissolved in buffer 1 (4.05 ml);

Fig. 2 Selected region from selective ^{1}H-TOCSY spectra of (a) commercial NADH, and catalytic reduction of NAD$^+$ using ^{2}HCOONa with, (b) S112A; (c) S112K; (d) no Sav.

This journal is © The Royal Society of Chemistry 2015

Org. Biomol. Chem., 2015, 13, 357–360 | 359

Ir-stock solution: 10 mM [Cp*Ir(biot-p-L)Cl] (2.55 mg, 3.17 µmol) was dissolved in DMF-d_7 (317 µl).

Preparation of ATHase: Sav-mutant S112A (2.53 mg, assuming 3 free binding sites) was dissolved in buffer 1 (1.144 mL), and Ir-stock solution was added (11.6 µl).

Sav-mutant S112K (2.65 mg assuming 3 free binding sites) was dissolved in buffer 1 (1.195 ml), and Ir-stock solution was added (12.1 µl).

Sample without SAV mutant (intermediate solutions): buffer 1 (0.495 ml) and Ir-stock solution was added (5 µl). Mixing was achieved by means of a vortex mixer. Reaction set up: To buffer 1 (125 µL) was added buffer 2 (250 µl; final concentration of ^{2}HCOONa = 100 mM), ATHase (or intermediate solutions) (100 µl, final concentration of Ir = 20 µM) and NAD$^+$-stock solution (25 µl, final concentration = 500 µM).

The reaction was incubated and agitated at 30 °C and 200 rpm for 24 h by means of a Thermomixer (HLC Biotech Model MHR 23).

Subsequently D$_2$O (50 µl) was added and the NMR spectra recorded.

Abbreviations

NADH	Nicotinamide adenine dinucleotide (reduced form)
NAD$^+$	Nicotinamide adenine dinucleotide
NAD(P)H	Nicotinamide adenine dinucleotide (phosphate) (reduced form)

Acknowledgements

References

1 T. E. Benson, J. L. Marquardt, A. C. Marquardt, F. A. Etzkorn and C. T. Walsh, *Biochemistry*, 1993, **32**, 2024–2030.

2 R. E. Viola, P. F. Cook and W. W. Cleland, *Anal. Biochem.*, 1979, **96**, 334–340.

3 G. Ottolina, S. Riva, G. Carrea, B. Danieli and A. F. Buckmann, *Biochim. Biophys. Acta, Protein Struct.*, 1989, **998**, 173–178.

4 U. T. Bornscheuer, G. W. Huisman, R. J. Kazlauskas, S. Lutz, J. C. Moore and K. Robins, *Nature*, 2012, **485**, 185–194.

5 F. Hollmann, I. W. C. E. Arends, K. Buehler, A. Schallmey and B. Buhler, *Green Chem.*, 2011, **13**, 226–265.

6 F. Hollmann, I. W. C. E. Arends and D. Holtmann, *Green Chem.*, 2011, **13**, 2285–2314.

7 F. Leipold, S. Hussain, D. Ghislieri and N. J. Turner, *ChemCatChem*, 2013, **5**, 3505–3508.

8 M. Rodríguez-Mata, A. Frank, E. Wells, F. Leipold, N. J. Turner, S. Hart, J. P. Turkenburg and G. Grogan, *ChemBioChem*, 2013, **14**, 1372–1379.

9 H. Wu, C. Tian, X. Song, C. Liu, D. Yang and Z. Jiang, *Green Chem.*, 2013, **15**, 1773–1789.

10 C. E. Paul, I. W. C. E. Arends and F. Hollmann, *ACS Catal.*, 2014, **4**, 788–797.

11 R. Ruppert, S. Herrmann and E. Steckhan, *Tetrahedron Lett.*, 1987, **28**, 6583–6586.

12 M. de Torres, J. Dimroth, I. W. C. E. Arends, J. Keilitz and F. Hollmann, *Molecules*, 2012, **17**, 9835–9841.

13 V. Köhler, Y. M. Wilson, M. Dürrenberger, D. Ghislieri, E. Churakova, T. Quinto, L. Knörr, D. Häussinger, F. Hollmann, N. J. Turner and T. R. Ward, *Nat. Chem.*, 2013, **5**, 93–99.

14 M. Dürrenberger, T. Heinisch, Y. M. Wilson, T. Rossel, E. Nogueira, L. Knörr, A. Mutschler, K. Kersten, M. J. Zimbron, J. Pierron, T. Schirmer and T. R. Ward, *Angew. Chem., Int. Ed.*, 2011, **50**, 3026–3029.

15 V. Muñoz Robles, M. Dürrenberger, T. Heinisch, A. Lledós, T. Schirmer, T. R. Ward and J.-D. Maréchal, *J. Am. Chem. Soc.*, 2014, **136**, 15676–15683.

16 L. Brecker and D. W. Ribbons, *Trends Biotechnol.*, 2000, **18**, 197–202.

17 B. Morawski, G. Casy, C. Illaszewicz, H. Griengl and D. W. Ribbons, *J. Bacteriol.*, 1997, **179**, 4023–4029.

18 J. Wu, W. Tang, A. Pettman and J. Xiao, *Adv. Synth. Catal.*, 2013, **355**, 35–40.

19 Y. M. Wilson, M. Dürrenberger and T. R. Ward, Organometallic chemistry in protein scaffolds, in *Protein Engineering Handbook*, ed. S. Lutz and U. T. Bornscheuer, Wiley-VCH Verlag GmbH & Co. KGaA, 2013, vol. 3, pp. 215–241.

20 H. Kessler, H. Oschkinat, C. Griesinger and W. Bermel, *J. Magn. Reson.*, 1986, **70**, 106–133.

21 A. Bax and D. G. Davis, *J. Magn. Reson.*, 1985, **65**, 355–360.

360 | *Org. Biomol. Chem.*, 2015, **13**, 357–360

This journal is © The Royal Society of Chemistry 2015